Compare TR & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | OGN |
|---|---|---|
| Founded | 1896 | 1923 |
| Country | United States | United States |
| Employees | 2100 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | TR | OGN |
|---|---|---|
| Price | $43.01 | $6.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 117.9K | ★ 3.0M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | 0.84% | ★ 1.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.42 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | $32.36 | ★ $8.31 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.13 | $5.69 |
| 52 Week High | $44.27 | $14.70 |
| Indicator | TR | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 39.63 |
| Support Level | $40.07 | N/A |
| Resistance Level | $43.37 | $7.87 |
| Average True Range (ATR) | 1.26 | 0.24 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 75.14 | 51.79 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.